Health
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findi
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"image","alt":"Indivior Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Indivior Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/a420cc32e120a253fc3fcae6c1c87744"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ML_FPTXSJAb3kX1MzGZ4MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/a420cc32e120a253fc3fcae6c1c87744","width":300,"height":85},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ML_FPTXSJAb3kX1MzGZ4MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/a420cc32e120a253fc3fcae6c1c87744","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine","length":212,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":383,"olType":false},{"type":"text","content":"RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD).“Collectively, these studies highlight the benefits of sustained treatment with monthly injectable buprenorphine, including reduced relapse risk and fewer serious complications that often drive acute care use,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings also emphasize the importance of proactively identifying patients at risk of treatment discontinuation and supporting continued access to evidence‑based medications for opioid use disorder.”","length":933,"tagName":"p"},{"type":"text","content":"One retrospecti...